- Home
- FUSB vs GANX Comparison
FUSB vs GANX Comparison
Compare FUSB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUSB | GANX |
|---|---|---|
| Founded | 1952 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 76.4M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FUSB | GANX |
|---|---|---|
| Price | $16.35 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 5.3K | ★ 609.8K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.47 | $1.41 |
| 52 Week High | $16.50 | $4.34 |
Technical Indicators
Market Signals| Indicator | FUSB | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 47.56 |
| Support Level | $15.75 | $1.73 |
| Resistance Level | N/A | $2.09 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 100.00 | 48.74 |
Price Performance
Historical ComparisonAbout FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.